This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Brainstorms

Preemptive Analgesia: Is Pain Less Costly When You Pre-Pay For It?

Stephen M. Stahl, MD, PhD

Published: December 15, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

A novel treatment concept is evolving in psychopharmacology, namely, that the same treatments that can reduce symptoms in patients who already have a psychiatric disorder may also prevent symptoms in high-risk individuals who do not yet have a psychiatric disorder.1 Thus, the mechanism whereby symptomatic suffering is relieved may also be related to the mechanism of preventing disease progression.1 Last month we discussed how atypical antipsychotics may not only treat the symptoms of schizophrenia, but also prevent the progression of high-risk individuals to schizophrenia.2


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...